Cipla USFDA nods for Advair, Ventolin launches in FY27

What Cipla announced on July 27

Cipla Ltd said it has received approval from the United States Food and Drug Administration (USFDA) for its generic version of Advair Diskus (fluticasone propionate and salmeterol inhalation powder). The approval covers the company’s Abbreviated New Drug Application (ANDA) for all three strengths of the product. Cipla disclosed the update through a stock exchange filing. The company described the product as a therapeutically equivalent version of Advair Diskus, a combination therapy used in asthma and chronic obstructive pulmonary disease (COPD). Cipla said the product is expected to be launched in the United States in the second quarter of financial year 2026-27. The company also positioned the approval as a step in its US respiratory strategy.

US approval details: strengths and therapy area

The approval was granted for the 100/50 mcg, 250/50 mcg and 500/50 mcg strengths of the inhalation powder. These are the strengths commonly used across patient segments based on severity and clinical need. Cipla’s filing noted the product is a combination of fluticasone propionate and salmeterol in a dry powder inhaler (DPI) format. The company linked the product to treatment of asthma and COPD, where fixed-dose combinations are widely prescribed. While Cipla did not disclose pricing or market share expectations in the filing, it did share the planned launch window. The emphasis remained on regulatory clearance and readiness for commercialisation in the US market.

A milestone for Cipla’s US manufacturing network

Cipla said this approval represents its first dry powder inhaler (DPI) approval from its US-based manufacturing network. It called the clearance a milestone in the company’s expansion of complex respiratory capabilities in the United States. In the context of inhalation products, regulatory approvals can also act as proof-points for manufacturing controls and device-process integration. Cipla did not provide plant-level details in the disclosure, but it linked the milestone to its US network. The company also signalled that the approval supports a broader respiratory pipeline strategy. The update comes as inhalation products remain one of the more complex segments in US generics.

Ventolin generic: AB-rated approval and planned launch

Separately, Cipla and its wholly-owned subsidiary Cipla USA Inc. disclosed final USFDA approval for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation. The company described it as the first AB-rated generic equivalent of Ventolin HFA, which was originally marketed by GlaxoSmithKline. Cipla said the product is used to treat or prevent bronchospasms. It also stated the product is indicated for treating or preventing bronchospasm in patients aged 4 years and older with reversible obstructive airway disease, and for preventing exercise-induced bronchospasm. Cipla expects the product to launch in the first half of FY 2026-27 in the US. In another disclosure summarised in the provided text, the Ventolin generic was also described as the first commercial metered dose inhaler (MDI) product manufactured from Cipla’s new US facility.

Broker views: Citi catalyst watch and ICICI Securities upgrade

Citi reiterated a Buy rating and put Cipla on a 90-day positive catalyst watch, citing a near-term sequence of US approvals and a domestic recovery theme. In Citi’s framing, the gVentolin launch planned in H1 FY27 and a gFlovent approval were highlighted as two critical US triggers. The text also notes that no PDUFA date or ANDA confirmation has been disclosed publicly for the referenced trigger, and the timeline remains unconfirmed. Separately, ICICI Securities upgraded Cipla to ‘Buy’ from ‘Add’ and raised its target price to ₹1,550 (from ₹1,450, as stated in the provided text). ICICI Securities also pointed to a pipeline of eight respiratory drugs, naming gAdvair, gSymbicort and gQvar, along with peptide assets such as gVictoza.

Market reaction and price points mentioned

Cipla shares ended at ₹1,416.00 on the BSE, down by ₹5.10, or 0.36%, on the day of the Advair approval disclosure. The provided text also contains another market datapoint from a different date: as of April 23, 2026 at 12:05 PM, Cipla’s share price on the NSE was trading at ₹1,286.50, up by 4.06% from the previous close. These two figures reflect different time windows referenced across the inputs. No additional volume data or broader index movement was provided in the text. The stock’s response, as described, indicates the market was weighing multiple moving parts, including US launches and competitive intensity.

Competitive context around Advair generics

The inputs also reference an earlier development where Respirent Pharmaceuticals and Lannett received final USFDA approval for a generic version of Advair Diskus. That development was described as negative for Cipla at the time because Cipla had filed its own generic version as early as 2020 and had been awaiting final approval. Street estimates in the provided text suggested peak sales potential of around USD 100 million for Cipla’s Advair generic, with a potential launch expected in the second half of FY27 in that earlier context. Nuvama was cited as flagging that rising competitive intensity could be detrimental for Cipla, increasing market share risk and impacting peak sales expectations for the Advair opportunity. The July 27 filing, however, indicates Cipla now has an approved ANDA for generic Advair Diskus across all strengths and a stated launch plan in Q2 FY 2026-27.

Compliance and filing backdrop: facilities and pending products

The provided text also notes that an inspection of Medispray Laboratories Private Limited, a Cipla subsidiary, ended with a “VAI” status (Voluntary Action Indicated). Separately, Cipla said it filed two generic respiratory drug applications with the USFDA in the last quarter, including a generic version of Symbicort and one other undisclosed inhalation product. The background also mentions that Cipla’s original Advair filing faced approval delays due to unresolved facility compliance issues and that a warning letter delayed launch timelines for its generic Advair in the US. In addition, Cipla had earlier indicated plans to file its generic Advair product application from an alternative site by mid-FY 2025, with approval possible toward the end of the next fiscal year if execution stayed on track.

Key approvals and timelines at a glance

Market impact: what the approvals change for Cipla

The two USFDA approvals strengthen Cipla’s respiratory portfolio in the US, particularly in complex inhalation formats. Cipla’s disclosures also place clear launch windows around FY 2026-27, which gives investors defined milestones to track. The Ventolin generic being described as the first AB-rated generic equivalent and tied to a new US facility is framed as a validation of Cipla’s US inhalation manufacturing capability. At the same time, the competitive environment for Advair generics is already active, based on the earlier approvals referenced in the inputs. Broker commentary in the provided text focuses on a sequence of US approvals and launches as potential near-term stock catalysts, while also acknowledging that some timelines remain unconfirmed for certain products.

Conclusion

Cipla’s July 27 update adds a fresh USFDA approval for generic Advair Diskus across all strengths, with a Q2 FY 2026-27 launch plan, alongside its AB-rated generic Ventolin approval with a H1 FY 2026-27 launch plan. The company is also linking these approvals to a broader build-out of complex respiratory capabilities from its US manufacturing network. Investors will likely track execution against the stated launch timelines, and any further US regulatory updates referenced by brokerages where timelines are still unconfirmed.